Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

MET amplification is a frequently observed genomic aberration in solid tumors. We conducted a phase I trial to evaluate dose-limiting toxicity (DLT) and recommended phase II dose (RP2D) for the combination therapy. The following dose levels were tested in this single-arm phase I study: docetaxel as...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Lee, Sujin, Park, Minhwa, Park, Se Hoon, Park, Joon Oh, Lim, Ho Yeong, Park, Young Suk, Kang, Won Ki, Gangolli, Esha A., Shin, Hyeongchan, Kim, Kyoung-Mee, Hollingsworth, Simon J., Mortimer, Peter G.S., Lee, Jeeyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348337/
https://www.ncbi.nlm.nih.gov/pubmed/30695737
http://dx.doi.org/10.1016/j.tranon.2018.12.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348337/
https://www.ncbi.nlm.nih.gov/pubmed/30695737
http://dx.doi.org/10.1016/j.tranon.2018.12.009

Ejemplares similares